NURIX THERAPEUTICS, INC. Operating Lease, Expense
NURIX THERAPEUTICS, INC. (NRIX) reported Operating Lease, Expense of $2.60 million for the 3-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. operating lease, expense for the quarter ending 2026-05-31 was $2.60M, a 29.73% decline year-over-year.
- NURIX THERAPEUTICS, INC. operating lease, expense for the quarter ending 2026-02-28 was $2.60M, a 18.18% increase year-over-year.
- NURIX THERAPEUTICS, INC. operating lease, expense for the quarter ending 2025-11-30 was $3.50M, a 59.09% increase year-over-year.
- NURIX THERAPEUTICS, INC. operating lease, expense for the quarter ending 2025-08-31 was $3.90M, a 77.27% increase year-over-year.
- NURIX THERAPEUTICS, INC. operating lease, expense for fiscal 2025 was $13.30M, a 47.78% increase from fiscal 2024.
- NURIX THERAPEUTICS, INC. operating lease, expense for fiscal 2024 was $9.00M, a 32.35% increase from fiscal 2023.
- NURIX THERAPEUTICS, INC. operating lease, expense for fiscal 2023 was $6.80M, a 15.25% increase from fiscal 2022.
- NURIX THERAPEUTICS, INC. operating lease, expense for fiscal 2022 was $5.90M, a 55.26% increase from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 3 month as first filed | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 9 month as first filed | Operating Lease, Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-05-31 | $2.60M 10-Q · filed 2026-07-09 | $5.20M 10-Q · filed 2026-07-09 | $8.70M derived: sum of 3 quarters · filed 2026-07-09 | $12.60M derived: sum of 4 quarters · filed 2026-07-09 | ||
| 2026-02-28 | $2.60M 10-Q · filed 2026-04-08 | $6.10M derived: sum of 2 quarters · filed 2026-04-08 | $10.00M derived: sum of 3 quarters · filed 2026-04-08 | $13.70M derived: sum of 4 quarters · filed 2026-07-09 | ||
| 2025-11-30 | $3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $7.40M derived: sum of 2 quarters · filed 2026-01-28 | $11.10M derived: sum of 3 quarters · filed 2026-07-09 | $13.30M 10-K · filed 2026-01-28 | ||
| 2025-08-31 | $3.90M 10-Q · filed 2025-10-09 | $7.60M derived: sum of 2 quarters · filed 2026-07-09 | $9.80M 10-Q · filed 2025-10-09 | $12.00M derived: sum of 4 quarters · filed 2026-07-09 | ||
| 2025-05-31 | $3.70M 10-Q · filed 2026-07-09 | $5.90M 10-Q · filed 2026-07-09 | $8.10M derived: sum of 3 quarters · filed 2026-07-09 | $10.30M derived: sum of 4 quarters · filed 2026-07-09 | ||
| 2025-02-28 | $2.20M 10-Q · filed 2026-04-08 | $4.40M derived: sum of 2 quarters · filed 2026-04-08 | $6.60M derived: sum of 3 quarters · filed 2026-04-08 | $8.80M derived: sum of 4 quarters · filed 2026-04-08 | ||
| 2024-11-30 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $4.40M derived: sum of 2 quarters · filed 2026-01-28 | $6.60M derived: sum of 3 quarters · filed 2026-01-28 | $9.00M 10-K · filed 2026-01-28 | ||
| 2024-08-31 | $2.20M 10-Q · filed 2025-10-09 | $4.40M derived: sum of 2 quarters · filed 2025-10-09 | $6.80M 10-Q · filed 2025-10-09 | $9.00M derived: sum of 4 quarters · filed 2026-01-28 | ||
| 2024-05-31 | $2.20M 10-Q · filed 2025-07-09 | $4.50M 10-Q · filed 2025-07-09 | $6.80M derived: sum of 3 quarters · filed 2026-01-28 | $8.30M derived: sum of 4 quarters · filed 2026-01-28 | ||
| 2024-02-29 | $2.30M 10-Q · filed 2025-04-08 | $4.60M derived: sum of 2 quarters · filed 2026-01-28 | $6.10M derived: sum of 3 quarters · filed 2026-01-28 | $7.60M derived: sum of 4 quarters · filed 2026-01-28 | ||
| 2023-11-30 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $3.80M derived: sum of 2 quarters · filed 2026-01-28 | $5.30M derived: sum of 3 quarters · filed 2026-01-28 | $6.80M 10-K · filed 2026-01-28 | ||
| 2023-08-31 | $1.50M 10-Q · filed 2024-10-11 | $3.00M derived: sum of 2 quarters · filed 2024-10-11 | $4.50M 10-Q · filed 2024-10-11 | $6.00M derived: sum of 4 quarters · filed 2025-01-28 | ||
| 2023-05-31 | $1.50M 10-Q · filed 2024-07-11 | $3.00M 10-Q · filed 2024-07-11 | $4.50M derived: sum of 3 quarters · filed 2025-01-28 | $6.00M derived: sum of 4 quarters · filed 2025-01-28 | ||
| 2023-02-28 | $1.50M 10-Q · filed 2024-04-10 | $3.00M derived: sum of 2 quarters · filed 2025-01-28 | $4.50M derived: sum of 3 quarters · filed 2025-01-28 | $6.00M derived: sum of 4 quarters · filed 2025-01-28 | ||
| 2022-11-30 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | $3.00M derived: sum of 2 quarters · filed 2025-01-28 | $4.50M derived: sum of 3 quarters · filed 2025-01-28 | $5.90M 10-K · filed 2025-01-28 | ||
| 2022-08-31 | $1.50M 10-Q · filed 2023-10-12 | $3.00M derived: sum of 2 quarters · filed 2023-10-12 | $4.40M 10-Q · filed 2023-10-12 | $5.60M derived: sum of 4 quarters · filed 2023-10-12 | ||
| 2022-05-31 | $1.50M 10-Q · filed 2022-07-07 | $2.80M 10-Q · filed 2023-07-13 | $4.10M derived: sum of 3 quarters · filed 2023-04-13 | $5.00M derived: sum of 4 quarters · filed 2023-04-13 | ||
| 2022-02-28 | $1.40M 10-Q · filed 2023-04-13 | $2.60M derived: sum of 2 quarters · filed 2023-04-13 | $3.50M derived: sum of 3 quarters · filed 2023-04-13 | $4.40M derived: sum of 4 quarters · filed 2023-04-13 | ||
| 2021-11-30 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $2.10M derived: sum of 2 quarters · filed 2023-02-09 | $3.00M derived: sum of 3 quarters · filed 2023-02-09 | $3.80M 10-K · filed 2023-02-09 | ||
| 2021-08-31 | $900.00K 10-Q · filed 2022-10-06 | $1.80M derived: sum of 2 quarters · filed 2022-10-06 | $2.60M 10-Q · filed 2022-10-06 | $3.42M derived: sum of 4 quarters · filed 2022-10-06 | ||
| 2021-05-31 | $900.00K 10-Q · filed 2022-07-07 | $1.70M 10-Q · filed 2022-07-07 | $2.52M derived: sum of 3 quarters · filed 2022-07-07 | $3.32M derived: sum of 4 quarters · filed 2022-07-07 | ||
| 2021-02-28 | $800.00K 10-Q · filed 2022-04-08 | $1.62M derived: sum of 2 quarters · filed 2022-04-08 | $2.42M derived: sum of 3 quarters · filed 2022-04-08 | $3.12M derived: sum of 4 quarters · filed 2022-04-08 | ||
| 2020-11-30 | $823.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $1.62M derived: sum of 2 quarters · filed 2022-01-28 | $2.32M derived: sum of 3 quarters · filed 2022-01-28 | $3.02M 10-K · filed 2022-01-28 | ||
| 2020-08-31 | $800.00K 10-Q · filed 2021-10-14 | $782.00K 10-Q · filed 2020-10-14 | $1.50M derived: sum of 2 quarters · filed 2021-10-14 | $2.20M 10-Q · filed 2021-10-14 | $2.24M 10-Q · filed 2020-10-14 | $2.90M derived: sum of 4 quarters · filed 2022-01-28 |
| 2020-05-31 | $700.00K 10-Q · filed 2021-07-13 | $1.50M 10-Q · filed 2021-07-13 | $2.10M derived: sum of 3 quarters · filed 2022-01-28 | $2.86M derived: sum of 4 quarters · filed 2022-01-28 | ||
| 2020-02-29 | $700.00K 10-Q · filed 2021-04-13 | $1.40M derived: sum of 2 quarters · filed 2022-01-28 | $2.16M derived: sum of 3 quarters · filed 2022-01-28 | |||
| 2019-11-30 | $697.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $1.46M derived: sum of 2 quarters · filed 2022-01-28 | $2.93M 10-K · filed 2022-01-28 | |||
| 2019-08-31 | $764.00K 10-Q · filed 2020-10-14 | $2.23M 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |